Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
02:36:58 EDT Sun 05 May 2024
Enter Symbol
or Name
USA
CA



Z:NNVC - NANOVIRICIDES INC - http://www.nanoviricides.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
NNVC - Z0.11.08·1.380.21.13-0.0701-5.826.426801.12  1.1699  1.102.00  1.0019:43:52Apr 3015 min RT 2¢

Recent Trades - Last 10 of 80
Time ETExPriceChangeVolume
19:43:52Z1.20 25
18:32:42Z1.16-0.0410
18:10:55Z1.280.084
16:37:54Z1.18-0.021
15:55:45Z1.1299-0.07014,000
15:55:45Z1.135-0.06580
15:55:30Z1.125-0.07578
15:52:00Z1.12-0.08132
15:50:17Z1.13-0.0720
15:42:32Z1.13-0.072

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-04-30 06:33U:NNVCNews ReleaseNanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon
2024-02-15 06:31U:NNVCNews ReleaseNanoViricides Has Filed its Quarterly Report - NV-387 Clinical Trial Healthy Subjects Part Successfully Completed, COVID Patient Treatment on the Horizon
2024-02-01 06:22U:NNVCNews ReleaseClinical Trial Demonstration of Safety and Tolerability of NV-CoV-2 Has Implications Beyond COVID Treatment, Explains NanoViricides - NV-387 Could be As Revolutionary as Antibiotics
2024-01-29 06:31U:NNVCNews ReleaseSafety in Multiple-Ascending-Dose Healthy Subjects Clinical Trial Part Successfully Established for the NanoViricides Ultra-Broad-Spectrum Antiviral Drug NV-CoV-2 with No Adverse Events Found
2024-01-04 06:31U:NNVCNews ReleaseNanoViricides to Present at the Biotech Showcase in San Fransisco
2023-11-29 13:33U:NNVCNews ReleaseNanoViricides updates progress on Phase 1a/1b clinical trial of antiviral drug candidate NV-387
2023-11-28 06:42U:NNVCNews ReleaseThe Phase 1a/1b Human Clinical Trial of NV-CoV-2, the Company ¢ € ™s Broad-Spectrum Antiviral Drug, Has Successfully Completed the First Part (Phase 1a), Reports NanoViricides
2023-11-15 06:47U:NNVCNews ReleaseNanoViricides Has Filed its Quarterly Report - NV-387 Broad-Spectrum Antiviral in Clinical Trials Has Additional Applications
2023-11-14 06:46U:NNVCNews ReleaseBroad-Spectrum Antiviral NV-387 (NV-CoV-2) in Phase 1a/1b Clinical Trial is Highly Effective in an Animal Model for MPox and Smallpox Drug Development
2023-10-16 06:47U:NNVCNews ReleaseNanoViricides, Inc. Has Filed its Annual Report: Broad-spectrum Antiviral NV-387 (NV-CoV-2) in Phase 1a/1b Clinical Trial is Highly Active Against Coronaviruses as well as RSV
2023-10-12 06:46U:NNVCNews ReleaseNanoViricides, Inc. to Present at the Partnership Opportunities in Drug Delivery Conference in Boston on October 16, 2023 at 6:07pm ET
2023-09-27 08:46U:NNVCNews ReleaseMulti-Billion Dollar Treatment Market For Lung Infection That Causes Over 200,000 Hospitalizations Annually With Elderly, Young At Most Risk Has Game-Changing New Entrant
2023-08-31 08:01U:NNVCNews ReleaseNanoViricides progressing well with new Covid study
2023-08-21 06:45U:NNVCNews ReleaseThe Phase 1a/1b Human Clinical Trial of NV-CoV-2, the Company ¢ € ™s Broad-Spectrum Antiviral Drug, is Progressing Successfully, Reports NanoViricides
2023-07-19 09:16U:NNVCNews ReleaseSARS-CoV-2 Is Not Done Yet ƒ ¢ ‚ € ‚ ” Could This New Drug In Clinical Trials Be The Safest Option For Treating COVID-19?
2023-07-13 08:33U:NNVCNews ReleaseNanoViricides testing oral gummy and syrup Covid-19 treatment - Proactive Research Analyst
2023-07-11 09:26U:NNVCNews ReleaseNovel Nanomedicine Platform With Pipeline Of Antivirals Goes To Human Trials ƒ ¢ ‚ € ‚ “ What Other Viruses Could This COVID Treatment Target?
2023-07-11 06:46U:NNVCNews ReleaseCompany ¢ € ™s Broad-Spectrum Antiviral NV-387 Has Demonstrated Excellent Effectiveness in RSV in a Lethal Lung Disease Animal Model, Reports NanoViricides
2023-07-06 09:02U:NNVCNews ReleaseNanoViricides Inc. (NYSE American: NNVC) Begins Long-Awaited Clinical Trials For Its Anti-Viral Nanomedicine NV-CoV-2, Oral, Amid Continuing Need For COVID Treatment
2023-07-06 06:45U:NNVCNews ReleaseClinical Trial of Broad-Spectrum Antiviral Drug NV-CoV-2 is Progressing Well, Says NanoViricides - NV-CoV-2 is Positioned to Fulfill Many Unmet Medical Needs